To evaluate the potential of the CypA/CD147 axis as a therapeutic target for NSCLC CSC elimination, we investigated the anticancer effects and underlying molecular mechanisms of the natural CypA inhibitors, C9 and CsA, on the growth of NSCLC CSCs in the present study. The gene discussed is PPIA; the disease is non-small cell lung carcinoma.